Reservoir-Type Subcutaneous Implantable DevicesContaining Porous Rate Controlling Membranes forSustained Delivery of Risperidone
Implantable drug delivery systems are crucial for achieving sustained deliveryof active compounds to specific sites or systemic circulation. In this study, anovel reservoir-type implant combining a biodegradable rate-controllingmembrane with a drug-containing core prepared using direct compressiontec...
| Autores: | , , , , , , |
|---|---|
| Formato: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2025 |
| País: | España |
| Recursos: | Universidad de Sevilla (US) |
| Repositorio: | idUS. Depósito de Investigación de la Universidad de Sevilla |
| OAI Identifier: | oai:idus.us.es:11441/174410 |
| Acesso em linha: | https://hdl.handle.net/11441/174410 https://doi.org/10.1002/adhm.202403689 |
| Access Level: | acceso abierto |
| Palavra-chave: | Implantable devices Poly(caprolactone) Porous membranes Risperidone Sustained delivery |
| Resumo: | Implantable drug delivery systems are crucial for achieving sustained deliveryof active compounds to specific sites or systemic circulation. In this study, anovel reservoir-type implant combining a biodegradable rate-controllingmembrane with a drug-containing core prepared using direct compressiontechniques is developed. The membrane is composed of poly(caprolactone)(PCL), and risperidone (RIS) served as the model drug. Characterization ofboth membranes and direct compressed pellets includes hardness testing,optical coherence tomography, mercury intrusion porosimetry, and surfacemorphology observation. In vitro release studies of RIS reveal that higher drugloading in the pellets extended-release duration up to 70 days whenincorporated into membranes with four layers. Increasing the number ofmembrane layers slows the release rate further, ranging from 70 to 170 daysdepending on membrane thickness. Biocompatibility studies demonstratethat these implantable devices are non-toxic and biocompatible with cells invitro. In vivo studies conduct in male Wistar rats demonstrate sustainedrelease of RIS, with plasma levels showing a significant increasepost-implantation at a relatively constant rate for up to 49 days. These resultsindicate that the developed implants have the potential to provide long-actingdrug delivery to the systemic circulation. |
|---|